



# Unique Regulation of the DosR Regulon in the Beijing Lineage of *Mycobacterium tuberculosis*

Pilar Domenech,<sup>a,b</sup> Jason Zou,<sup>a,c</sup> Alexandra Averback,<sup>a,c</sup> Nishath Syed,<sup>a,c</sup>  
Daniele Curtis,<sup>a,c</sup> Samuel Donato,<sup>a,c</sup> Michael B. Reed<sup>a,b,d</sup>

Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada<sup>a</sup>; Department of Medicine, McGill University, Montreal, Quebec, Canada<sup>b</sup>; Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada<sup>c</sup>; McGill International TB Centre, Montreal, Quebec, Canada<sup>d</sup>

**ABSTRACT** The DosR regulon, a set of 48 genes normally expressed in *Mycobacterium tuberculosis* under conditions that inhibit aerobic respiration, is controlled via the DosR-DosS/DosT two-component system. While the regulon requires induction in most *M. tuberculosis* isolates, for members of the Beijing lineage, its expression is uncoupled from the need for signaling. In our attempts to understand the mechanistic basis for this uncoupling in the Beijing background, we previously reported the identification of two synonymous single-nucleotide polymorphisms (SNPs) within the adjacent Rv3134c gene. In the present study, we have interrogated the impact of these SNPs on *dosR* expression in wild-type strains, as well as a range of *dosR-dosS-dosT* mutants, for both Beijing and non-Beijing *M. tuberculosis* backgrounds. In this manner, we have unequivocally determined that the C601T *dosR* promoter SNP is the sole requirement for the dramatic shift in the pattern of DosR regulon expression seen in this globally important lineage. Interestingly, we also show that DosT is completely nonfunctional within these strains. Thus, a complex series of evolutionary steps has led to the present-day Beijing DosR phenotype that, in turn, potentially confers a fitness advantage in the face of some form of host-associated selective pressure.

**IMPORTANCE** *Mycobacterium tuberculosis* strains of the Beijing lineage have been described as being of enhanced virulence compared to other lineages, and in certain regions, they are associated with the dramatic spread of multidrug-resistant tuberculosis (TB). In terms of trying to understand the functional basis for these broad epidemiological phenomena, it is interesting that, in contrast to the other major lineages, the Beijing strains all constitutively overexpress members of the DosR regulon. Here, we identify the mutational events that led to the evolution of this unique phenotype. In addition, our work highlights the fact that important phenotypic differences exist between distinct *M. tuberculosis* lineages, with the potential to impact the efficacy of diagnosis, vaccination, and treatment programs.

**KEYWORDS** Tuberculosis, DosR regulon, strain variation, evolution, *Mycobacterium tuberculosis*

Despite being an ancient disease, human tuberculosis (TB) resulting from infection with *Mycobacterium tuberculosis* still remains a leading cause of death worldwide as a consequence of multiple contributing factors, including drug resistance, HIV coinfection, and inadequate access to high-quality health care (1). Furthermore, recent evidence suggests that the level of genetic diversity that exists among distinct *M. tuberculosis* isolates was previously underestimated and has the potential to impact pathogenicity, as well as to limit the effectiveness of current diagnostic and therapeutic interventions (2–4).

Received 21 September 2016 Accepted 25 October 2016

Accepted manuscript posted online 31 October 2016

**Citation** Domenech P, Zou J, Averback A, Syed N, Curtis D, Donato S, Reed MB. 2017. Unique regulation of the DosR regulon in the Beijing lineage of *Mycobacterium tuberculosis*. *J Bacteriol* 199:e00696-16. <https://doi.org/10.1128/JB.00696-16>.

**Editor** Thomas J. Silhavy, Princeton University

**Copyright** © 2016 American Society for Microbiology. All Rights Reserved.

Address correspondence to Michael B. Reed, [michael.reed@mcgill.ca](mailto:michael.reed@mcgill.ca).

The identification of specific single-nucleotide polymorphisms (SNPs) and/or large-sequence polymorphisms (LSPs) has enabled the classification of *M. tuberculosis* isolates into 7 major strain lineages (lineages 1 to 7) that show a degree of geographic restriction (5, 6). From an epidemiological perspective, it is particularly interesting to note that the incidence of TB resulting from the major Beijing subbranch of lineage 2 (also known as the East Asian lineage) is reported to be increasing disproportionately in multiple settings, and it is often associated with the spread of multidrug-resistant (MDR) *M. tuberculosis* (7–12). This has led to frequent speculation that strains belonging to the Beijing lineage possess unique phenotypic attributes that confer an increased ability to transmit and/or cause disease, as well as an increased capacity to acquire antibiotic resistance (10, 11). Indeed, it has recently been demonstrated that members of this lineage acquire resistance to multiple antibiotics *in vitro* at a rate that is up to 10-fold higher than that of lineage 4 strains (including the laboratory strain *M. tuberculosis* H37Rv), due to an increased basal mutation frequency. In the same paper, modeling simulations used by Ford et al. indicated that the probability of *de novo* MDR arising in patients infected with Beijing strains is more than 20-fold higher than for non-Beijing strain infections (13). Although the exact mechanism(s) underlying this enhanced mutation rate has yet to be defined, we and other groups have suggested that perturbations in regulatory, metabolic, or structural pathways that exist in the Beijing strains potentially account for an alteration in antibiotic sensitivity/tolerance (2, 11, 13, 14). In turn, this could provide a mechanism by which an increased proportion of cells are able to survive drug exposure, thereby increasing the potential for the acquisition of specific resistance mutations (15).

One striking example of a regulatory perturbation unique to the Beijing lineage involves the DosR regulon, a 48-member regulon that includes a diverse array of genes involved in anaerobic respiration, metabolism (nucleotide, carbon, and lipid), and stress responses, and which is controlled through a two-component signaling system comprising the transcription factor DosR and one of two sensor kinases, DosS or DosT (16, 17). The DosR regulon normally serves as the primary mechanism by which *M. tuberculosis* responds to changes in the redox environment as a result of hypoxia or nitric oxide (NO) exposure (18–21). These signals are encountered as part of the host granulomatous response and are proposed to be among the most critical stimuli for the development of dormancy and latent TB (22–24). Mechanistic links between DosR and other “master regulators,” such as WhiB3 and the PhoPR two-component regulatory system, have also recently been described, suggestive of a wider stress-associated regulatory network linking hypoxia and redox adaptation (DosR-WhiB3), with cell wall lipid biosynthesis (WhiB3-PhoP) (25, 26). In contrast to the other *M. tuberculosis* lineages, the Beijing lineage constitutively overexpress members of the DosR regulon, a phenotype we first described in 2007 (14, 27) and that has since been independently confirmed in multiple laboratories (28, 29). Thus, the DosR regulon is always activated in the Beijing isolates, even in the absence of the aforementioned external redox signals.

In 2010, we reported several Beijing-specific mutations within the *dosR-dosS-dosT* two-component regulatory system that coincide with the appearance of the constitutive DosR phenotype (30). The one on which we initially focused as being a potential contributor to the Beijing DosR phenotype was a frameshift mutation in the DosT sensor kinase gene. We originally hypothesized that the C-terminal kinase domain may have been constitutively active in the absence of the upstream regulatory sequence. However, gene complementation assays employing both wild-type and mutant versions of *dosT* in diverse strain backgrounds suggested that the mutation in *dosT* was not directly responsible for the constitutive DosR regulon phenotype (30). Next, we investigated a novel 350-kb gene duplication that was identified in members of the most recently evolved Beijing strains (14, 31). The presence of this duplication, which includes a second copy of the Rv3134c-*dosR-dosS* operon, does increase the extent of DosR regulon expression; however, gene disruption studies coupled with the finding that it is not uniformly present among all Beijing strains highlight the fact that the

duplication is not the underlying cause of the constitutive DosR phenotype (14, 32). Furthermore, recent work by our laboratory has shown that this large chromosomal duplication event is rapidly selected for as a consequence of *in vitro* growth (32).

In the present study, we have reinvestigated the two SNPs we identified in the coding region of the Rv3134c gene that lies immediately adjacent to *dosR* and is included as part of the *dosR-dosS* operon. We originally discounted these SNPs on account of the fact that they are both synonymous and are located quite some distance upstream (>200 bp) of the *dosR* start codon (30). Herein, using a variety of approaches, we comprehensively demonstrate that one of these SNPs is the sole cause of the constitutive DosR overexpression phenotype that typifies the widespread Beijing lineage. Our data also serve to emphasize the dramatic effect that the evolution of a single regulatory mutation can have on shaping lineage-specific gene expression in *M. tuberculosis*. In turn, these alterations in gene expression, in the absence of environmental signaling, might contribute to the reputed epidemiologic success of the Beijing strains.

## RESULTS

**DosR regulon is the major feature that distinguishes gene expression between Beijing and non-Beijing strains.** In order to compare the gene expression profiles of a “modern” Beijing isolate versus a “pre-Beijing” lineage 2 (East Asian) isolate, we performed whole-genome microarray analyses with HN878 (14, 33) and 98\_1663 (5) with reference to the H37Rv (ATCC) laboratory strain. HN878 is a modern Beijing isolate belonging to the region of difference 142 (RD142) Beijing subbranch, while 98\_1663 is an ancestral lineage 2 strain lacking the RD207 deletion that is responsible for the characteristic Beijing spoligotyping profile (5, 34, 35). In contrast, H37Rv is a non-Beijing lineage 4 strain. When HN878, 98\_1663, and H37Rv were grown under standard *in vitro* conditions, the ancestral isolate displayed an overall pattern of gene expression very similar to that of H37Rv. We identified only 5 genes that were differentially expressed, although the pattern of expression of these genes appears to be shared with the modern HN878 Beijing isolate (Fig. 1). Of particular note, members of the ESX-1 type VII secretion system that are critical for full virulence of *M. tuberculosis* (36–39) were significantly overexpressed in both of these isolates compared to H37Rv, including the *esxA* (*esat-6*), *esxB* (*cfp-10*), and *espl* genes. It should be noted that for the HN878 arrays, the relative expression level of *esxA* (+1.9) fell just below the Z-score threshold of >2.0. Although there were other findings of potential interest in these comparisons, for example, the VapBC-17 and VapBC-47 toxin-antitoxin complexes and certain *mce* (mammalian cell entry) genes were differentially regulated compared to H37Rv, from the point of view of the present study, the most striking observation was the very large influence that DosR appears to have on shaping the differential gene expression profile of HN878 compared to both H37Rv and the 98\_1663 (pre-Beijing) isolate. Indeed, of the 34 genes that we reproducibly detected as being overexpressed in HN878 relative to H37Rv via microarray, >40% (14/34) were members of the DosR regulon (Fig. 1). Included in this list are *dosR* and *dosS*, encoding the main regulatory components of the regulon. Other examples of note include *tgs1*, encoding a triacylglycerol synthase whose expression has been associated with triglyceride accumulation under hypoxic conditions (40); *hspX*, encoding an  $\alpha$ -crystallin-like chaperonin that is inducible under stress conditions, including hypoxia (41); *hrp1*, encoding a protein of unknown function that is reportedly able to be used to discriminate between latent and active TB infection (42, 43); and multiple genes from the Rv2623 to Rv2630 cluster that have recently been described as being upregulated by isoniazid (INH) treatment, specifically within infected macrophages (44).

Overall, these findings reaffirm and expand upon our initial description of the constitutive overexpression of the DosR regulon in the Beijing lineage that was based on comparative real-time PCR analysis of a select set of genes (14, 27, 30). Next, as a step toward developing the tools necessary to understand the evolution and functional significance of this dramatic shift in the pattern of DosR regulon gene expression, we

HN878 / H37Rv			
ID	Z score	Gene	
Rv2527	9.13	vapC17	> 4.0
Rv2627c	7.48	CHP	2.0 to 4.0
Rv2628	6.88	UHP	-2.0 to -4.0
Rv3131	4.58	Rv3131	< -4.0
Rv3132c	4.47	dosS	
Rv3155	4.13	nuoK	
Rv2623	4.08	TB31.7	
Rv3143	3.93	Rv3143	
Rv2626c	3.76	hrp1	
Rv2107	3.74	PE22	
Rv0569	3.35	Rv0569	
Rv3876	3.34	espl	
Rv2031c	3.26	hspX	
Rv3130c	3.12	tgsl	
Rv3127	3.01	CHP	
Rv3551	2.98	Rv3551	
Rv2526	2.98	vapB-17	
Rv3134c	2.95	Rv3134c	
Rv3874	2.94	cfp10	
Rv0990c	2.90	Rv0990c	
Rv0171	2.83	mce1 C	
Rv0451c	2.82	mmpS4	
Rv0826	2.71	CHP	
Rv1733c	2.62	Rv1733c	
Rv0172	2.60	mce1D	
Rv2674	2.55	msrB	
Rv1996	2.50	Rv1996	
MT0694	2.40	MT0694	
Rv3831	2.30	Rv3831	
Rv3133c	2.28	dosR	
Rv0878c	2.24	PPE13	
Rv2341	2.07	lppQ	
Rv1495	2.06	mazF4	
Rv1157c	2.03	Rv1157c	
Rv2393	-2.10	che1	
Rv0642c	-2.35	mmaA4	
Rv2991	-2.54	CHP	
Rv3429	-2.86	PPE59	
MT2880.2	-2.96	MT2880.2	
Rv2082	-3.27	CHP	
Rv0836c	-3.53	Rv0836c	
Rv2077c	-3.56	Rv2077c	
Rv3407	-4.52	vapB47	
Rv3408	-4.73	vapC47	


  

98_1663/H37Rv		
ID	Z score	Gene
Rv3874	3.07	esxB
Rv3131	2.43	Rv3131
Rv3875	2.19	esxA
Rv3429	-2.00	PPE59
Rv3407	-4.92	vapB47

**FIG 1** The DosR regulon is the major feature that distinguishes gene expression between Beijing and non-Beijing strains. Heatmaps of the microarray-based expression profiles comparing Beijing isolate HN878 and pre-Beijing isolate 98\_1663 to the Euro-American strain H37Rv are shown. Data represent the mean from three arrays for each comparison. Only genes whose expression differs from that in H37Rv by a Z-score of more than  $\pm 2$ -fold are indicated. Values in green represent genes that are significantly overexpressed relative to H37Rv, while those in red indicate genes that are significantly repressed relative to H37Rv. Genes highlighted in yellow are members of the DosR regulon.

continued our ongoing efforts aimed at identifying the underlying molecular basis of this Beijing-specific phenotype.

**Beijing-specific *dosR* promoter region confers constitutive overexpression of *dosR*.** In our 2010 publication that documents the *dosT* frameshift mutation, we also



**FIG 2** The Beijing-specific *dosR* promoter region confers constitutive overexpression of *dosR*. (A) Partial sequence alignment of nucleotides 501 to 612 of the Rv3134c gene (nucleotide positions 3500444 to 3500555; numbering based on H37Rv). A total of 31 *M. tuberculosis* complex isolates were analyzed, 18 of which belong to the East Asian lineage. Of these, 13 were from the Beijing sublineage (East Asian [EA] groups 2 to 5). The positions of the C507G (left) and C601T (right) synonymous SNPs are highlighted. Only the C601T SNP is unique to the Beijing lineage. (B) Genomic organization of the Rv3134c-*dosR*-*dosS* operon. The approximate positions of the C507G and C601T SNPs found in the Rv3134c gene of *M. tuberculosis* Beijing isolates are shown. Arrows indicate previously identified promoter sequences, while D and P refer to distal and proximal binding sites, respectively, of the DosR-dependent hypoxic T<sub>H</sub> promoter (45, 46). A schematic representation of the inserts present in the various plasmids introduced into wild-type H37Rv is shown: pNS3 and pDC4 contain a 3,359-bp fragment that includes Rv3134c truncated at nucleotide 305, along with the complete *dosR* and *dosS* gene sequences; pNS5 and pDC5 contain a 1,883-bp fragment that includes 392 bp upstream of the Rv3134c gene, along with the complete Rv3134c and *dosR* gene sequences; and pNS6 and pDC6 contain a 4,049-bp fragment that includes 392 bp upstream of the Rv3134c gene in addition to the Rv3134c, *dosR*, and *dosS* genes. The pNS3, pNS5, and pNS6 plasmids contain the 507C and 601C H37Rv allele, while pDC4, pDC5, and pDC6 contain the 507G and 601T HN878 (Beijing) allele. (C) qRT-PCR analysis of *dosR* expression in H37Rv transformed with the plasmids indicated in panel B. For reference, wild-type H37Rv and HN878 are also included. Results are shown as relative quantities (R.Q.), using *sigA* as the normalizing gene. The error bars represent standard deviations calculated as indicated in Materials and Methods.

reported the identification of three synonymous SNPs within the 3.9-kb region surrounding *dosR* that includes Rv3131, *dosS*, and Rv3134c (30). Two of these SNPs were termed C507G and C601T, based on their position within the Rv3134c coding region. The C507G SNP was present in both the ancestral East Asian (95\_1848) and modern Beijing strains (HN878 and W210) that were sequenced, while the C601T SNP was specific to the modern Beijing strains. We also identified a single G1068A substitution within *dosS* of the modern Beijing strains. As indicated above, we initially discounted the C507G and C601T SNPs on account of the fact that they are synonymous and are located >200 bp upstream of the *dosR* start codon. However, after eliminating the *dosT* mutation as the root cause of the Beijing constitutive DosR phenotype, we decided to look more closely at these SNPs on account of their relative proximity to the T<sub>1</sub> and T<sub>2</sub> transcription start sites (TSS) that had previously been reported for *dosR* (45, 46). We postulated that SNPs within this same region potentially impact *dosR* transcription.


To start, we sequenced the region of Rv3134c containing the C507G and C601T SNPs from representatives of each of the 6 major *M. tuberculosis* lineages that had been described at that time, including 3 to 5 representatives of each of the 5 RD-based subgroups of the East Asian lineage/lineage 2. Of these 5 subgroups, groups 2 to 5 represent the Beijing sublineage (27, 47, 48). Interestingly, the C507G SNP is restricted to the phylogenetically related East African/Indian (lineage 3) and East Asian lineages, while the C601T SNP is unique to the Beijing sublineage of the East Asian lineage (Fig. 2A). Thus, as with the *dosT* frameshift mutation (30), the presence of the C601T SNP correlates precisely with the occurrence of the constitutive DosR regulon phenotype. Meanwhile, the East African/Indian strains that bear only the C507G SNP display a level of *dosR* expression that is equivalent to that in H37Rv (see Fig. S1 in the supplemental material).

To further investigate the specific contribution of the aforementioned SNPs to the expression of *dosR* within the Beijing strain background, we generated a series of plasmid constructs capable of integrating at the nonessential mycobacteriophage L5 attachment site (*attB*) and that harbor distinct segments of the Rv3134c-*dosR*-*dosS* operon (Fig. 2B). Two versions of each of these segments were cloned: a wild-type non-Beijing version based on the H37Rv sequence (pNS series) and a Beijing version based on the sequence found in HN878 (pDC series). The pNS3 and pDC4 plasmids contain *dosR* and *dosS*, along with the 3' region of Rv3134c that includes the C507G and C601T SNPs, in the case of pDC4. This region also includes the T<sub>1</sub> and T<sub>2</sub> TSS that have been reported to partially drive basal *dosR* expression (45, 46). Plasmids pNS5 and pDC5 contain full-length Rv3134c and *dosR* (without *dosS*), in addition to the promoter region of Rv3134c that includes both DosR-dependent (T<sub>H</sub>) and DosR-independent promoter elements (45, 46). Finally, pNS6 and pDC6 contain the full-length Rv3134c-*dosR*-*dosS* operon, including the Rv3134c promoter region. All six of these constructs were transformed into wild-type H37Rv, and the expression of *dosR* was analyzed via quantitative real-time PCR (qRT-PCR) and normalized against expression of the *sigA* gene encoding the housekeeping sigma factor. In a comparison of the pNS and pDC plasmids, which differ only by the presence of the C507G and C601T SNPs present in the pDC series, there was a very striking effect of the Beijing-specific sequence (pDC4, pDC5, and pDC6) on *dosR* expression, even when placed in the non-Beijing (H37Rv) background (Fig. 2C). Indeed, the pNS-transformed strains all behaved much like the parental H37Rv strain (albeit with slightly elevated *dosR* expression due to the presence of a second *dosR* copy). On the other hand, all the pDC-transformed H37Rv strains exhibited *dosR* expression levels that bore a remarkable resemblance to the wild-type HN878 strain. In one case (pDC5), *dosR* expression exceeded the level observed for HN878. This is likely attributable to the relatively small size of the plasmid insert in this case, allowing for more efficient transcription. Together, these data are highly suggestive that the C507G and/or C601T SNPs are directly contributing to the development of the constitutive *dosR* phenotype displayed by the Beijing strains (including HN878).

**C601T promoter SNP is sufficient to cause the Beijing DosR phenotype.** To further refine our understanding of the mechanistic requirements necessary for the constitutive overexpression of *dosR*, we repeated several of the above-mentioned transformations within the *dosR* knockout (KO) background, for both the H37Rv (non-Beijing) and HN878 (Beijing) strains. In this manner, all *dosR* expression was derived from the exogenous copy of *dosR* contained on the integrated plasmid. In addition, several new plasmid constructs were generated to test the specific role of the individual C601T SNP, as well as the role of *dosR* itself on the evolution of the Beijing phenotype (Fig. 3A).

In both the *dosR* KO backgrounds, the effect of introducing the Beijing version of the Rv3134c-*dosR*-*dosS* operon was again very striking. In a comparison of the pNS6 and pDC6 plasmids, which differ only in the presence of the C507G and C601T SNPs (as described above), we observed an approximately 10-fold increase in *dosR* expression for both the H37Rv and HN878 transformants (Fig. 3B). Moreover, when the pAA3 plasmid (a hybrid containing the H37Rv allele at position 507 and the HN878 allele at position 601) was introduced into both *dosR* KO mutant backgrounds, the level of *dosR* expression was virtually identical to that seen for wild-type HN878 as well as the pDC6-containing strains. This important result clearly demonstrated that the presence of the Beijing-specific C601T promoter SNP is sufficient to drive the constitutive overexpression of *dosR* within the Beijing lineage. Indeed, we were able to recreate the same phenotype in the non-Beijing (H37Rv) background just by introducing this single mutation (Fig. 3B).

Next, we investigated the impact of *dosR* activation status, as well as the complete absence of *dosR*, on transcription arising from the Beijing promoter region. This was done in order to determine if *dosR* itself has any role to play in activating transcription in the presence of the C601T mutation. Plasmid pAA6 is a derivative of pDC6 (contain-



**FIG 3** The C601T promoter SNP is sufficient to cause the Beijing DosR phenotype. (A) Genomic organization of the *Rv3134c-dosR-dosS* operon, as in Fig. 2. The position of the Asp<sup>54</sup>Glu mutation (pAA6) is also indicated. A schematic representation of the inserts included in the plasmids used to transform *dosR* KO mutants of H37Rv and HN878 is shown. pAA3 and pAA6 contain a 4,049-bp fragment that includes 392 bp upstream of the *Rv3134c* gene in addition to the *Rv3134c*, *dosR*, and *dosS* genes. pAA3 contains a 507C (H37Rv) and 601T (HN878) hybrid allele (i.e., it has only the C601T SNP), while pAA6 contains the 507G and 601T HN878 allele along with a T/A transversion at position 161 of *dosR* that replaces Asp54 with Glu54. This renders DosR nonphosphorylatable. pAR2 contains a 3,393-bp fragment that incorporates 392 bp upstream of *Rv3134c* in addition to the *Rv3134c* and *dosS* genes (dashed line, no *dosR*). It is also based on the 507G and 601T HN878 allele. The pNS6, pDC6, pDC4, and pDC5 plasmids are all described in the legend to Fig. 2. (B to D) qRT-PCR analysis of *dosR* (B and C) and *dosS* (D) expression in wild-type, *dosR* KO mutant, and complemented strains. Results are shown as relative quantities (R.Q.), using *sigA* as the normalizing gene. The error bars represent standard deviation.


ing both C507G and C601T SNPs) that has an Asp-to-Glu mutation at position 54 of DosR that renders it nonphosphorylatable; hence, it is unable to be activated by either the DosS or DosT sensor kinase (16). As seen in Fig. 3C, the level of *dosR* expression for both the H37Rv and HN878 *dosR* KO strains transformed with pAA6 was not substantially different from that of either wild-type HN878 or the pDC transformants. From this, we conclude that activated DosR is not responsible for mediating transcription from the novel Beijing *dosR* promoter region. Likewise, pAR2 is a derivative of pDC6 that lacks *dosR* entirely. As expected, the KO strains transformed with this plasmid are devoid of *dosR* expression (Fig. 3C). However, the level of *dosS* expression in these strains was identical to that of wild-type HN878 or the pDC6 transformants (Fig. 3D). Hence, the C601T SNP is able to exert its effect on transcription completely independently of the DosR protein. Last, given that the level of *dosS* expression in the pDC6-containing strains was approximately 10-fold higher than in the *dosR* KOs (Fig. 3D), yet the level of *dosR* in the pDC5 and pDC6 transformants was equivalent (Fig. 3B and C), we deduce that the C601T SNP is also able to function independently of *dosS*, a fact we later confirmed in the HN878  $\Delta dosR \Delta dosS$  mutant strain background that has no residual *dosS* expression (data not shown). Thus, the presence of the C601T promoter SNP is the sole feature of the *dosR* operon that is required for initiating the unique *dosR* phenotype displayed by the Beijing lineage.

**Constitutive DosR regulon phenotype of the Beijing lineage does not impact virulence within the mouse model of infection.** To begin to interrogate the Beijing DosR phenotype from a functional perspective, we performed a series of aerosol mouse infections in order to examine the impact of constitutive (Beijing) versus inducible (non-Beijing) DosR overexpression on bacterial growth within the lungs and spleens of infected animals, as well as its impact on animal survival. Note that several prior studies had already validated the mouse as being a suitable model for distinguishing Beijing and non-Beijing *M. tuberculosis* strains on the basis of animal survival (49, 50). These low-dose aerosol infections (10 to 20 CFU/lung) were carried out for the following strains: wild-type HN878 (Beijing), HN878 in which both *dosR* and *dosS* were disrupted (*dosRS* KO mutant), and the HN878 *dosRS* KO mutant complemented with either pNS6 (non-Beijing Rv3134c-*dosR-dosS* operon) or pDC6 (Beijing Rv3134c-*dosR-dosS* operon). Thus, the only difference between the complemented strains is the presence of the two *dosR* promoter SNPs (C507G and C601T). The expression of *dosR*, as well as an independent marker of DosR regulon activation, Rv3130c (*tgs1*), was examined in these strains in order to confirm their expected phenotypes prior to use (Fig. S2).

In a comparison of the growth of wild-type HN878 to that of the double-knockout mutant (*dosRS* KO) in the lungs of infected mice, we observed an approximately 1-log<sub>10</sub> reduction in CFU for the strain lacking both *dosR* and *dosS* between weeks 4 and 9 postinfection (Fig. 4A). However, as the infection progressed beyond 9 weeks, this difference in CFU seemed to resolve. By 28 weeks postinfection, there was no longer any detectable CFU difference. Interestingly, the reduction in bacterial CFU seen between 4 and 9 weeks with the double-KO mutant was not observed in the spleens (Fig. 4B). This suggests that any defect attributable to the loss of DosR and DosS may be specific to the lungs, at least within the context of this mouse model. In terms of the animal survival study (12 mice/group) that was halted after 9 months, disrupting both *dosR* and *dosS* in the HN878 background had no statistically significant effect on the median survival time of these mice compared to the wild-type group (236 versus 269 days, respectively) (Fig. 4C).

Although the pDC6-complemented strain was more closely in line with the lung CFU of the wild-type HN878 at 4 and 9 weeks postinfection than the pNS6 complement, the most plausible interpretation of the data presented is that there is no biologically relevant difference between the two strains (Fig. 4A). The same observation can be made from the spleen CFU data (Fig. 4B). For the animal survival experiments, the median survival times of the pNS6 and pDC6 groups were 202 and 217 days, respectively (Fig. 4C). Again, there was no significant difference between the two groups.





**FIG 4** The constitutive DosR regulon phenotype of the Beijing lineage does not impact virulence within the mouse model of infection. (A and B) B6D2/F1 mice were infected via aerosol with wild-type (wt) HN878, an HN878 *dosRS* KO mutant, HN878 *dosRS* KO::pNS6 (H37Rv allele), and HN878 *dosRS* KO::pDC6 (HN878 allele). Bacterial numbers were monitored at the indicated times postinfection by harvesting lungs (A) and spleens (B) of infected mice. Results are expressed as the average log<sub>10</sub> CFU obtained from five mice at each time point. Error bars represent the standard deviation. \*,  $P = 0.047$  for the HN878 wt versus the HN878 *dosRS* KO mutant at 28 days postinfection; \*\*,  $P = 0.009$  for the HN878 wt versus the HN878 *dosRS* KO mutant at 63 days postinfection. (C) Survival curve for 12 mice per group infected with the same strains as those for panels A and B. Analysis of these data was carried out using the Kaplan-Meier method, and a log rank test was used to determine the statistical significance of observed differences in survival (GraphPad Prism, version 3.0; GraphPad Software, CA). No significant survival differences were observed between the 4 strains tested in this case.

Although there was a trend early on toward the pNS6-infected animals dying more rapidly, this was not sustained.


Overall, we conclude that in the low-dose aerosol model of infection employing C57BL6/J  $\times$  DBA/2J F1 mice, there is no impact on virulence for strains that constitutively overexpress *dosR* along with members of the DosR regulon.

**DosT sensor kinase is completely nonfunctional in the Beijing lineage.** We have previously examined the effect of the Beijing-specific *dosT* frameshift mutation (Fig. 5A) on *dosR* expression and activation through a series of gene complementation assays carried out in wild-type Beijing and non-Beijing strain backgrounds (30). These initial data suggested that the mutation in *dosT* was not the direct cause of the constitutive *dosR* overexpression seen in the Beijing lineage. Our subsequent examination of the C601T *dosR* promoter mutation (see above) confirms this observation. However, a clear interpretation regarding the effect of the *dosT* frameshift mutation was difficult in the aforementioned study due to the fact that the strains examined were diploid for *dosT* (wild-type and mutant copies) and also retained functional DosS. To conclusively demonstrate whether expression of the Beijing *dosT* gene has any effect on *dosR* expression and/or the ability of DosR to be activated in the presence of nitric oxide (NO), herein, we generated an H37Rv strain in which both *dosS* and *dosT* were disrupted (*dosST* KO mutant) prior to carrying out the complementation assays with wild-type or mutant *dosT*. Thus, the strains analyzed in this case expressed only the wild-type or mutant (Beijing) version of *dosT*, in the complete absence of the DosS sensor kinase.


Expression of *dosT* containing the frameshift mutation had no impact on the basal level of *dosR* expression that was observed in the parental *dosST* KO mutant strain (Fig. 5B). Similarly, there was no increase in *dosR* expression following treatment with diethylenetriamine-nitric oxide (DETA-NO), a compound that spontaneously releases NO when in solution. In contrast, expression of wild-type *dosT* resulted in *dosR* levels that were slightly above those in wild-type H37Rv under both treated and nontreated conditions. This can be explained by the fact that *dosT* was being overexpressed by the *hsp60* promoter in these strains compared to the normal levels seen in H37Rv (Fig. 5C). Overall, these data confirm our original finding that the Beijing *dosT* gene is not functionally contributing to the constitutive DosR regulon phenotype.

In our previous study, we also speculated that a truncated version of DosT may be expressed in an active form that lacks the N-terminal GAF regulatory domain (Fig. 5A) (51). To look at what forms of the DosT protein are produced as a result of the Beijing frameshift mutation, in the present study, we have expressed N- and C-terminal FLAG epitope-tagged DosT (mutant and wild type) in *Mycobacterium smegmatis*, followed by Western immunoblotting of total protein lysates with anti-FLAG antibodies. When wild-type DosT was expressed with a FLAG epitope located at either the N or C terminus, we readily detected the predicted 63-kDa DosT fusion protein (Fig. 5D). However, in the case of the mutant *dosT*, we did not observe any novel protein species distinct from those appearing in the negative control (a plasmid bearing wild-type *dosT* without any FLAG epitope). Therefore, it appears as if *dosT* bearing the Beijing frameshift mutation is either no longer expressed, or any translation product that arises is rapidly being degraded. This finding is consistent with the gene expression data described above (Fig. 5B), indicating that the mutated *dosT* gene is nonfunctional.

To ascertain the effect that a loss in DosT sensor kinase function has on the cell in terms of its ability to induce the DosR regulon, we took our H37Rv *dosRST* triple-KO mutant and transformed it with the integrative pNS6 and pDC6 plasmids containing the non-Beijing and Beijing versions of the Rv3134c-*dosR*-*dosS* operon, respectively (see Fig. 2B). We then compared the expression of *dosR* and Rv3130c (*tgs1*; a marker of DosR regulon induction) in untreated *in vitro* cultures versus those treated for 2 h with 150  $\mu$ M DETA-NO. With respect to the expression of *dosR* and Rv3130c, it is clear that the loss of DosT had no detrimental impact on inducibility when the C601T SNP was present (Fig. 6). However, when the wild-type non-Beijing promoter was used (pNS6), there was an approximately 2-fold reduction in the maximal levels of *dosR* and Rv3130c



**FIG 5** The DosT sensor kinase is completely nonfunctional in the *M. tuberculosis* Beijing lineage. (A) A schematic representation of the DosT protein showing the relative position of each of its conserved functional domains (<http://www.rcsb.org/pdb/protein/P9WVGK1>) is shown. The approximate location of the frameshift mutation (G775) identified within *dosT* of Beijing strains that is predicted to result in the introduction of a premature termination codon (STOP) is indicated, as is the autophosphorylation site at residue His392 (17). (B and C) qRT-PCR analysis of *dosR* (B) and *dosT* (C) expression in the H37Rv wild type, the H37Rv *dosST* KO mutant, and the H37Rv *dosST* KO mutant complemented with the *dosT* gene from either H37Rv (wt) or HN878 (mut). Results are shown as relative quantities (R.Q.), using *sigA* as the normalizing gene. The error bars represent standard deviations. Gray bars indicate samples prepared from cultures treated with the NO donor diethylenetriamine-nitric oxide (DETA-NO) for 2 h prior to RNA extraction. (D) Western immunoblotting using anti-FLAG M2 peroxidase to probe reduced protein extracts prepared from *M. smegmatis* transformants harboring N- or C-terminal FLAG epitope-tagged mutant (mut; Beijing) or wild-type (wt; non-Beijing) DosT. The negative control (neg.) corresponds to protein extracts from *M. smegmatis* carrying wild-type *dosT* (i.e., with no FLAG epitope). The arrow indicates the position of the full-length DosT protein. Molecular mass markers are indicated along the right.



**FIG 6** The *dosT* defect in Beijing isolates has no impact on the functionality of the DosR regulon. (A and B) qRT-PCR analysis of *dosR* (A) and Rv3130c (B) expression in H37Rv and HN878 wild-type strains (wt), as well as the H37Rv *dosTRS* triple-KO mutant complemented with either pNS6 (harboring the Rv3134c promoter and complete Rv3134c-*dosR*-*dosS* operon from H37Rv) (Fig. 2) or pDC6 (harboring the Rv3134c promoter and complete Rv3134c-*dosR*-*dosS* operon from HN878) (Fig. 2). Results are shown as relative quantities (R.Q.), using *sigA* as the normalizing gene. The error bars represent standard deviation as per Materials and Methods. Gray bars indicate samples prepared from cultures treated with the NO donor diethylenetriamine-nitric oxide (DETA-NO) for 2 h prior to RNA extraction.

expression that were attained following induction with NO. This is likely attributable to the fact that the “resting” levels of the two genes are 18 to 20 times higher when the Beijing SNP is present. In the presence of DETA-NO, the level of induction of Rv3130c when *dosR* was expressed from the C601T SNP-containing promoter was 9-fold, versus 75-fold when the SNP was absent (Fig. 6B). For *dosR* itself, there appeared to be no further induction upon DETA-NO addition in the pDC6-complemented strain, compared to a 9-fold induction for the pNS6-complement and a 1.3-fold induction in the case of wild-type HN878 (Fig. 6A).

To summarize, the frameshift in *dosT* renders it a nonfunctional pseudogene in the Beijing lineage. However, as a result of the associated *dosR* promoter mutation, this *dosT* defect appears to have no impact on the functionality of the DosR regulon within this same set of strains.

## DISCUSSION

While we were in the process of conducting this study, Rose et al. published an article that combined *M. tuberculosis* genome sequence data with transcriptomics (RNA sequencing [RNA-seq]) in order to identify lineage-specific mutations that are associated with phenotypic diversity at the level of gene expression (29). In this manner, these authors identified the same C3500149T synonymous SNP in the *dosR* promoter region (referred to herein as the C601T SNP), which they showed correlated with a novel *dosR* transcript, as well as a strong overall enhancement of the DosR regulon response in the two Beijing strains they analyzed. While our data certainly confirm the predictions made by Rose et al., in the present study, we have also gone one step

further and set out to prove a causal relationship between the SNP we identified through sequence analysis (30) (Fig. 2A) and the constitutive Beijing DosR phenotype via a combination of traditional molecular approaches. In this manner, we have effectively satisfied the molecular Koch's postulates (52).

Rose et al. also suggest that the C3500149T SNP generates a novel  $-10$  TANNNT consensus motif, thereby effectively creating a new TSS within the *dosR* promoter region from which transcription is activated via the housekeeping SigA  $\sigma$  factor (29, 53–55). Although this seems a reasonable assumption, it has not been confirmed experimentally. Thus, it remains possible that a transcription factor other than SigA is involved in promoting transcription from this Beijing-specific promoter region, or if SigA is involved, it may be doing so in the presence of an additional transcriptional activator (56).

Aside from an early defect in bacterial replication in the *dosRS* double-KO mutant around weeks 4 to 9 that coincides with the early phases of development of the adaptive immune response, the results of our mouse aerosol infections do not point to any substantial benefit of the Beijing DosR regulon phenotype *in vivo*. However, as other research groups have demonstrated, the standard mouse model of infection may not be suitable for teasing apart differences between strains based solely around DosR expression (57–60). The granuloma-like cellular aggregations that form in the normal mouse lung appear not to develop areas of hypoxia; thus, any benefit to the bacteria that may arise due to continuous DosR regulon expression during the early phases of hypoxia development, for example, may not be observable within this model (61, 62). In this regard, rabbits, guinea pigs, monkeys or the Kramnik mouse model may be more informative in future efforts aimed at comparing the effect of the Beijing versus non-Beijing DosR phenotypes on pathogenesis (57, 59, 60, 62). The early delayed-growth phenotype seen with the *dosRS* KO mutant suggests that this strain may be at a disadvantage early on after T-cell-mediated immunity develops in the lung. This finding is interesting in light of reports that indicate that T cells specific to several DosR regulon antigens are generated during the course of natural infection, and in some cases, these antigens may be recognized more strongly in latently infected individuals (42, 43). Thus, given the apparent evolutionary benefit to *M. tuberculosis* that maintaining host recognition of critical T-cell antigens provides, the loss of the DosR regulon antigens in the double-KO mutant may render it more susceptible to prolonged inflammatory attack as a result of the diminished T-cell repertoire and, possibly, a delay in the resulting granulomatous response (63). This hypothesis awaits further investigation.

In our original 2007 description of constitutive DosR regulon overexpression within the Beijing lineage, we indicated a connection between the DosR phenotype and the marked triacylglyceride (TAG) accumulation we had also observed in these strains. This connection was made primarily on the basis of *tgs1* (Rv3130c), a triacylglycerol synthase, being overexpressed as part of the DosR regulon (27). In addition, TAG had been reported to accumulate in H37Rv under hypoxia and NO treatment, both of which induce the DosR regulon (40, 64). However, as part of the present study, we determined that constitutive *dosR* expression is not the underlying cause of the TAG accumulation seen in Beijing strains. For example, when the entire *dosR-dosS-dosT* system was knocked out in the Beijing background, the accumulation of TAG was unaffected (Fig. S3A). Similarly, when *dosR-dosS* was overexpressed in H37Rv from the pDC6 plasmid bearing the Beijing *dosR* promoter, no increase in TAG synthesis was detectable via thin-layer chromatography (Fig. S3A). However, an HN878  $\Delta tgs1$  mutant we have generated does accumulate slightly less TAG than the parental strain, suggestive of a partial role for *tgs1* in Beijing TAG synthesis that is independent of DosR (Fig. S3B). Thus, although both DosR regulon activation and TAG synthesis are associated with conditions leading to growth arrest in non-Beijing *M. tuberculosis* strains, these two phenotypes are seemingly uncoupled from the aforementioned signals within the Beijing lineage (i.e., they occur natively) and appear to be independent of each other. Moreover, neither phenotype has any noticeable impact on the *in vitro* (aerobic) growth rate

of Beijing strains, nor does reconstruction of the constitutive Beijing *dosR* phenotype in the non-Beijing H37Rv background (data not shown). Thus, while *dosR* activation and TAG synthesis may well be markers of dormancy or nonreplicative persistence, for example, when *M. tuberculosis* is placed under hypoxic conditions, by themselves, they are not sufficient to induce these physiological states. A similar observation has been made previously by Minch et al. (65). Our data also serve to reinforce the point that there is the potential for considerable metabolic flexibility among the different circulating *M. tuberculosis* lineages. Thus, understanding the metabolic flux of one particular strain, including a long-term lab-adapted strain, such as H37Rv, does not guarantee that we understand the individual metabolic nuances of all strains. We and others have previously highlighted the importance of considering the impact of *M. tuberculosis* genetic and metabolic diversity in the generation of future treatment and diagnostic programs (2, 4, 28, 66, 67).

Given the potential energetic cost associated with the dramatic shift in the pattern of DosR regulon expression observed for the Beijing lineage shown herein (Fig. 1) and elsewhere (27–30), it seems reasonable to expect that the evolution and maintenance of this phenotype must confer a significant survival or fitness advantage to the bacteria in response to some form of host-associated selective pressure. Presumably, the promoter mutation responsible for the constitutive *dosR* overexpression phenotype occurred early on in the evolution of the Beijing lineage, as it is conserved across all of the Beijing sublineages in the strains we have examined to date (Fig. 2a). Furthermore, based on the whole-genome sequences of 358 unique lineage 2 *M. tuberculosis* strains representing 15 countries (most within the East Asia region, including Russia), Luo et al. have independently determined that the C601T SNP in Rv3134c is phylogenetically informative for defining strains that belong to the Beijing lineage (12). Although the published estimates of exactly when the most recent Beijing sublineages evolved vary widely (from 8,000 to 200 years ago), in any case, they appear to have origins that are well before the modern era of antibiotics, *Mycobacterium bovis* BCG vaccination, or HIV (10, 12). Thus, the original selection event(s) that led to the Beijing promoter mutation is not related to any of these recently applied evolutionary forces. However, this certainly does not preclude the possibility that the Beijing DosR phenotype provides an added fitness benefit to these strains in the modern context of anti-TB drugs or the BCG vaccine. Therefore, it is theoretically possible that the constitutive overexpression of DosR has contributed to the recent global expansion of the Beijing lineage from its ancestral home in East Asia to eastern Europe and other parts of the globe (7, 8, 10, 12). Indeed, the recent associations between the Beijing lineage and drug resistance are most often recorded for countries in which the lineage has recently emerged (8, 11). The potential role of DosR in this process is intriguing in light of two recent reports: first, Ford et al. have demonstrated an up to 10-fold increase in the *in vitro* mutation rate of Beijing compared to non-Beijing (lineage 4) strains in response to multiple front-line anti-TB drugs (13). Second, Liu et al. have very recently shown that a large component of the transcriptional response of intracellular *M. tuberculosis* toward drug treatment is mediated via *dosR* (44). Liu et al. also showed that there is considerable overlap between the intracellular response of *M. tuberculosis* to anti-TB drugs and the stress conditions encountered as a result of immune activation. Thus, within the intracellular milieu, both antibiotic treatment and immune activation converge at the level of DosR regulon activation. In the same study, immune activation of *M. tuberculosis*-infected cells was tied to the development of antibiotic tolerance (44). Hence, it is of great interest to investigate the possibility that constitutive DosR regulon expression in the Beijing background contributes to either drug tolerance or resistance. This is also interesting in light of the precedent in the literature that implicates the WhiB3 and WhiB7 transcription factors in modifying *M. tuberculosis* drug susceptibility. Like DosR, both of these transcription factors are known to regulate the cellular response to redox stress (56, 68).

As with the *dosR* promoter mutation, the frameshift mutation that renders *dosT* nonfunctional is present across all sublineages (30). Although the relative timing of the

two events is still unknown, we feel that the evolution of the *dosT* mutation most likely represents a compensatory event that occurred secondary to the initial *dosR* promoter mutation, and it reflects the fact that maintaining a functional DosT kinase in this context serves no functional purpose. This is entirely consistent with previous suggestions that DosT acts as the “first responder” in terms of oxygen or NO sensing but plays no further role once DosS is induced by virtue of being a member of the DosR regulon and also part of the Rv3134c-*dosR*-*dosS* operon (69–72). In the context of the Beijing DosR phenotype, the early activatory role normally attributed to DosT appears to have been supplanted through the constitutive overexpression of *dosR*.

In summary, we have comprehensively demonstrated that the C601T *dosR* promoter mutation is the sole factor underlying the constitutive *dosR* overexpression phenotype unique to the Beijing *M. tuberculosis* lineage. In turn, this correlates with a dramatic shift in the overall pattern of DosR regulon gene expression within these strains that, bearing in mind the high energetic cost likely associated with maintaining this phenotype, almost certainly affords some form of survival or fitness advantage within the environment of the host. Other host-adaptive regulatory mutations described within the wider *M. tuberculosis* complex, such as those in the PhoPR and SigK systems, have been associated with broad evolutionary shifts linked to specific host species (73, 74). It will be intriguing in the future to determine if the lineage-specific DosR trait detailed herein also represents a bacterial adaptation to a specific host population or host-associated selective pressure. In addition, given the pleiotropic nature of the proteins encoded within the DosR regulon, it is undoubtedly important that we understand the impact of this phenotype, along with other examples of strain variation, on the long-term success of TB diagnosis, vaccination, and treatment programs.

## MATERIALS AND METHODS

**Chemicals, bacterial strains, and culture conditions.** All chemicals were supplied by Sigma-Aldrich, Inc., unless otherwise noted. *Escherichia coli* NEB 5-alpha (NEB) used for cloning was cultured in Luria-Bertani broth or agar (Difco). When necessary, ampicillin ( $100 \mu\text{g} \cdot \text{ml}^{-1}$ ), kanamycin ( $50 \mu\text{g} \cdot \text{ml}^{-1}$ ), hygromycin ( $200 \mu\text{g} \cdot \text{ml}^{-1}$ ; Wisent), or gentamicin ( $5 \mu\text{g} \cdot \text{ml}^{-1}$ ; Invitrogen) was added to the medium. *M. smegmatis* mc<sup>2</sup>155 and *M. tuberculosis* strains were grown in Middlebrook 7H9 broth (Difco) supplemented with 10% albumin-dextrose-catalase (ADC;  $8.1 \text{ g} \cdot \text{liter}^{-1}$  NaCl,  $50 \text{ g} \cdot \text{liter}^{-1}$  bovine serum albumin [BSA] Fraction V [Calbiochem],  $20 \text{ g} \cdot \text{liter}^{-1}$  glucose, 0.2% glycerol, and 0.05% Tween 80 or on Middlebrook 7H11 agar (Difco) supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) enrichment (as per ADC, plus  $0.6 \text{ ml} \cdot \text{l}^{-1}$  oleic acid, 3.6 mM NaOH). Kanamycin ( $25 \mu\text{g} \cdot \text{ml}^{-1}$ ), hygromycin ( $50 \mu\text{g} \cdot \text{ml}^{-1}$ ), or gentamicin ( $10 \mu\text{g} \cdot \text{ml}^{-1}$ ) was used as necessary. Treatment of *M. tuberculosis* with NO was accomplished by adding the NO donor diethylenetriamine-nitric oxide (DETA-NO) to early log-phase cultures (optical density at 600 nm [OD<sub>600</sub>], 0.2 to 0.3) at a final concentration of 150  $\mu\text{M}$  and incubating for 2 h at 37°C with constant mixing prior to RNA extraction. Control cultures were grown under identical conditions in the absence of DETA-NO.

*M. tuberculosis* H37Rv was originally obtained from the American Type Culture Collection (ATCC 27294). The majority of clinical *M. tuberculosis* isolates used in this study were originally reported as part of an earlier molecular epidemiology investigation (48) in which isolates were classified according to the presence of large-sequence polymorphisms (LSPs) (47). Isolate 98\_1663 was kindly provided by S. Gagneux (Swiss Tropical and Public Health Institute, Basel, Switzerland) and P. Small (Stony Brook University, Stony Brook, NY). Strain HN878 was originally obtained from J. Musser (Methodist Hospital Research Institute, Houston, TX) (75). The HN878-27 subclone derived in our laboratory (14) lacks the 350-kb genomic duplication generated *in vitro* by HN878 and certain other Beijing isolates, and it is referred to here as HN878 (32).

**General nucleic acid techniques.** *Taq* polymerase and dinucleoside triphosphates (dNTPs) were obtained from Thermo Scientific. PCR was carried out according to standard protocols (76), except, where necessary, 5 or 10% dimethyl sulfoxide (DMSO) was also included in the reaction mixtures. The primers used in this study are shown in Table S1 in the supplemental material. *M. tuberculosis* knockout (KO) strains were generated by homologous recombination using the system developed by Pelicic et al. (77). The plasmids used in this study are listed in Table 1. Specific details of how these plasmids were constructed are described in the supplemental material. The gene arrangement of each KO strain around the site of homologous recombination was confirmed by PCR, and their gene expression phenotypes were confirmed by qRT-PCR. The absence of the 350-kb duplication that can occur in strains belonging to groups 3 to 5 of the East Asian lineage was confirmed by PCR, as previously described (14, 32).

**Sequence analysis of the *dosR* promoter region.** A 647-bp fragment was generated by PCR using primers Rv3134c-M-F and *dosR*-B. This region corresponds to nucleotides 3499869 to 3500516 of the genome, numbered according to the H37Rv sequence provided in TubercuList (<http://tuberculist.epfl.ch/>) (78). This sequence harbors 574 bp at the 3' end of Rv3134c and 46 bp at the 5' end of *dosR*. Sanger

**TABLE 1** Plasmids used in this study

Name	Insert
pNS3	Truncated Rv3134c- <i>dosR-dosS</i> from H37Rv in pMV306-Kan; 507C plus 601C allele
pNS5	Rv3134c promoter-Rv3134c- <i>dosR</i> from H37Rv in pMV306-Kan; 507C plus 601C allele
pNS6	Rv3134c promoter-Rv3134c- <i>dosR-dosS</i> from H37Rv in pMV306-Kan; 507C plus 601C allele
pDC4	Truncated Rv3134c- <i>dosR-dosS</i> from HN878 in pMV306-Kan; 507G plus 601T allele
pDC5	Rv3134c promoter-Rv3134c- <i>dosR</i> from HN878 in pMV306-Kan; 507G plus 601T allele
pDC6	Rv3134c promoter-Rv3134c- <i>dosR-dosS</i> from HN878 in pMV306-Kan; 507G plus 601T allele
pAA3	Rv3134c promoter-Rv3134c- <i>dosR-dosS</i> from HN878 in pMV306-Kan; 507C plus 601T hybrid allele
pAA6	Rv3134c promoter-Rv3134c- <i>dosR-dosS</i> from HN878 in pMV306-Kan; 507G plus 601T, DosR (D54E)
pAR2	Rv3134c promoter-Rv3134c- <i>dosS</i> from HN878 in pMV306-Kan; 507G plus 601T allele (no <i>dosR</i> )
pdosT-wt	<i>dosT</i> from H37Rv in pMV361-Gent
pdosT-mut	<i>dosT</i> from HN878 (G775 frameshift mutation) in pMV361-Gent
pN-FLAGdosT-wt	5' FLAG-wild-type <i>dosT</i> in pMV361-Kan
pC-FLAGdosT-wt	Wild-type <i>dosT</i> -3' FLAG in pMV361-Kan
pN-FLAGdosT-mut	5' FLAG-mutant <i>dosT</i> (G775 frameshift mutation) in pMV361-Kan
pC-FLAGdosT-mut	Mutant <i>dosT</i> (G775 frameshift mutation)-3' FLAG in pMV361-Kan
pPR23Δ <i>dosR</i> +S	<i>dosR-kan-dosS</i> in pPR23; used for generating <i>M. tuberculosis dosR-dosS</i> KO mutants
pPR23Δ <i>dosT</i> /Hyg	<i>dosT-hyg-dosT</i> in pPR23; used for generating <i>M. tuberculosis dosT</i> KO mutants
pΔ <i>dosS</i> v2.0	<i>dosS-kan-dosS</i> in pPR23; used for generating <i>M. tuberculosis dosS</i> KO mutants
pPDM15	<i>dosR-hyg-dosR</i> in pPR23; used for generating <i>M. tuberculosis dosR</i> KO mutants
pPDM4	<i>tgsl-hyg-tgs1</i> in pPR23; used for generating <i>M. tuberculosis tgsl</i> KO mutants

sequencing of the reaction products was carried out at the McGill University and Génome Québec Innovation Centre.

**Microarray analysis.** Whole-genome transcriptome profiling was performed by microarray analysis of RNA, according to protocols previously described (79). In brief, 4  $\mu$ g of RNA was used in the preparation of cDNA labeled with either Cy3 or Cy5-NHS esters (GE Healthcare) via the aminoallyl indirect labeling method (80) in the presence of SuperScript III reverse transcriptase (Invitrogen). The *M. tuberculosis* whole-genome microarrays used in these experiments were kindly provided by F. McIntosh and M. Behr (McGill University) and are composed of 70-bp oligonucleotides (TB Array-Ready oligo set; Operon) printed in duplicate. The mean fluorescence values for each spot, minus the surrounding background, were used in the analysis. Spots flagged as misrepresentative or those with a negative value following background correction were excluded from further analysis. The fluorescence intensity ratios (Cy3/Cy5 or Cy5/Cy3) were calculated for each spot,  $\log_{10}$  transformed, and then normalized with respect to the mean value of all fluorescence ratios. A Z-score [ $Z = (\log_{10} \text{fluorescence ratio} - \text{mean})/\text{standard deviation}$ ] was calculated for each spot, and the Z-scores for each gene were averaged across all replicates. Two independent biological samples were analyzed for each *M. tuberculosis* strain (a total of 3 arrays for each comparison).

**qRT-PCR.** RNA was purified from cultures with an  $OD_{600}$  of 0.2 to 0.3, as previously described (18). Primer pairs DosR-RT-6-f and DosR-RT-6-r, dosTSYBR-F2 and dosTSYBR-R2, Rv3130c-F and Rv3130c-R, and DosS-F2 and DosS-R2 (Table S1) were used to quantify the expression of *dosR*, *dosT*, Rv3130c, and *dosS*, respectively, while primers SigA1-F and SigA1-R were used to quantify *sigA* for normalization purposes. The procedures used for first-strand cDNA synthesis and qRT-PCR were as described by Domenech and Reed (79). The relative standard curve method was used for quantification. Standard deviations (SD) were calculated according to the following formula as specified by Applied Biosystems (81):  $SD = (cv)(X)$ , where  $X$  is the ratio of the mean values of the nominator ( $n$ ) and denominator ( $d$ ).  $cv$  is the coefficient of variation (standard deviation normalized to the mean values for each gene) calculated from the following formula:  $cv = \sqrt{[(cv_n)^2 + (cv_d)^2]}$ . Three biological replicates were each analyzed in triplicate.

**Mouse infections.** Prior to infection, well-dispersed liquid cultures were adjusted to an  $OD_{600}$  of 0.4 and stored at  $-70^\circ\text{C}$  as 10% (vol/vol) glycerol stocks. Inocula were prepared by diluting these stocks to  $4 \times 10^6$  CFU/ml in phosphate-buffered saline (PBS)-Tween 80 (0.05%). Eight-week-old B6D2/F1 mice (The Jackson Laboratory) were infected using a Lovelace nebulizer (In-Tox) for 10 min. Bacteria were enumerated at 1, 14, 28, 63, and 196 days postinfection (5 mice per time point) by homogenizing the lungs and spleens of infected mice in 1 ml of 7H9 medium and plating 10-fold serial dilutions on 7H11-OADC medium containing PANTA antibiotic mixture (BD; 12 U/ml polymyxin B, 1.2  $\mu$ g/ml amphotericin B, trimethoprim, and azlocillin, and 4.8  $\mu$ g/ml nalidixic acid) to avoid contamination of the plates. Twelve mice were left in each group for the animal survival experiments. Survival proportions were calculated using the Kaplan-Meier method (82), and the Mann-Whitney test was used to determine the statistical significance of the observed survival differences (GraphPad Prism version 3.0; GraphPad Software, CA). All animal experiments were approved and carried out in accordance with the guidelines and regulations of the Animal Care Committee of McGill University.

**Protein techniques.** Crude protein extracts from *M. smegmatis* mc<sup>2</sup>155 transformants were prepared by bead-beating, according to the procedure described by Parish and Wheeler (83). Samples were added to an equal volume of 2 $\times$  reducing sample buffer (containing 8 M urea), boiled, and then electrophoresed in 10% acrylamide-bis-acrylamide (29:1) (Bio-Rad) SDS-PAGE, according to standard procedures (76). The monoclonal anti-FLAG M2-horseradish peroxidase (HRP) clone M2 (Sigma) and the Amersham



ECL detection system (GE Healthcare) were used for Western blotting, according to the manufacturer's instructions.

**Lipid analysis.** Apolar lipids were extracted as previously described (84). The presence of phthiocerol dimycoserate (PDIM) in all *M. tuberculosis* strains used in this study was confirmed by radiolabeling cultures with 0.1  $\mu$ Ci/ml of [ $^{14}$ C]propionic acid (1 mCi/37 MBq; American Radiolabeled Chemicals), and extracted lipids were analyzed by thin-layer chromatography (TLC) (silica gel 60 plates; EM Science) run three times in hexanes/ethyl acetate (98:2 [vol/vol]) (79). Triacylglyceride (TAG) content was analyzed by radiolabeling with 1  $\mu$ Ci/ml of [ $^{14}$ C(U)]glycerol (1 mCi/37 MBq; American Radiolabeled Chemicals) and analyzed as described above (27). TLC plates were visualized using a Storm 840 PhosphorImager (Molecular Dynamics).

**Accession number(s).** The data associated with this paper have been deposited in NCBI's Gene Expression Omnibus and are accessible with GEO series accession no. GSE83677.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/JB.00696-16>.

**TEXT S1**, PDF file, 0.8 MB.

## ACKNOWLEDGMENTS

We thank Anya Rog for her technical assistance throughout this project. We are also grateful to Marcel Behr and Fiona McIntosh (Research Institute of the McGill University Health Centre) for providing access to several of the *M. tuberculosis* strains and also the microarrays used in this study.

We declare no conflicts of interest.

This work was supported by Canadian Institutes of Health Research (CIHR) grant MOP115133 to M.B.R.

## REFERENCES

1. Harries AD, Dye C. 2006. Tuberculosis. *Ann Trop Med Parasitol* 100: 415–431.
2. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the *Mycobacterium tuberculosis* complex for the development of novel antibiotics and diagnostic tests of drug resistance. *Antimicrob Agents Chemother* 56:6080–6087. <https://doi.org/10.1371/journal.pbio.0060311>.
3. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, Roach JC, Kremer K, Petrov DA, Feldman MW, Gagneux S. 2008. High functional diversity in *Mycobacterium tuberculosis* driven by genetic drift and human demography. *PLoS Biol* 6:e311. <https://doi.org/10.1371/journal.pbio.0060311>.
4. Coscolla M, Gagneux S. 2014. Consequences of genomic diversity in *Mycobacterium tuberculosis*. *Semin Immunol* 26:431–444. <https://doi.org/10.1016/j.smim.2014.09.012>.
5. Comas I, Homolka S, Niemann S, Gagneux S. 2009. Genotyping of genetically monomorphic bacteria: DNA sequencing in *Mycobacterium tuberculosis* highlights the limitations of current methodologies. *PLoS One* 4:e7815. <https://doi.org/10.1371/journal.pone.0007815>.
6. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, Yeboah-Manu D, Bothamley G, Mei J, Wei L, Bentley S, Harris SR, Niemann S, Diel R, Aseffa A, Gao Q, Young D, Gagneux S. 2013. Out-of-Africa migration and Neolithic coexpansion of *Mycobacterium tuberculosis* with modern humans. *Nat Genet* 45: 1176–1182. <https://doi.org/10.1038/ng.2744>.
7. Cowley D, Govender D, February B, Wolfe M, Steyn L, Evans J, Wilkinson RJ, Nicol MP. 2008. Recent and rapid emergence of W-Beijing strains of *Mycobacterium tuberculosis* in Cape Town, South Africa. *Clin Infect Dis* 47:1252–1259. <https://doi.org/10.1086/592575>.
8. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. 2006. Beijing/W genotype *Mycobacterium tuberculosis* and drug resistance. *Emerg Infect Dis* 12:736–743. <https://doi.org/10.3201/eid1205.050400>.
9. Hanekom M, van der Spuy GD, Streicher E, Ndabambi SL, McEvoy CR, Kidd M, Beyers N, Victor TC, van Helden PD, Warren RM. 2007. A recently evolved sublineage of the *Mycobacterium tuberculosis* Beijing strain family is associated with an increased ability to spread and cause disease. *J Clin Microbiol* 45:1483–1490. <https://doi.org/10.1128/JCM.02191-06>.
10. Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rusch-Gerdes S, Mokrousov I, Aleksic E, Allix-Beguec C, Antierens A, Augustynowicz-Kopec E, Ballif M, Barletta F, Beck HP, Barry CE, III, Bonnet M, Borroni E, Campos-Herrero I, Cirillo D, Cox H, Crowe S, Crudu V, Diel R, Drobniewski F, Fauville-Dufaux M, Gagneux S, Ghebremichael S, Hanekom M, Hoffner S, Jiao WW, Kalon S, Kohl TA, Kontsevaya I, Lillebaek T, Maeda S, Nikolayevskyy V, Rasmussen M, Rastogi N, Samper S, Sanchez-Padilla E, Savic B, Shamputa IC, Shen A, Sng LH, Stakenas P, Toit K, Varaine F, Vukovic D, et al. 2015. Evolutionary history and global spread of the *Mycobacterium tuberculosis* Beijing lineage. *Nat Genet* 47:242–249. <https://doi.org/10.1038/ng.3195>.
11. Parwati I, van Crevel R, van Soolingen D. 2010. Possible underlying mechanisms for successful emergence of the *Mycobacterium tuberculosis* Beijing genotype strains. *Lancet Infect Dis* 10:103–111. [https://doi.org/10.1016/S1473-3099\(09\)70330-5](https://doi.org/10.1016/S1473-3099(09)70330-5).
12. Luo T, Comas I, Luo D, Lu B, Wu J, Wei L, Yang C, Liu Q, Gan M, Sun G, Shen X, Liu F, Gagneux S, Mei J, Lan R, Wan K, Gao Q. 2015. Southern East Asian origin and coexpansion of *Mycobacterium tuberculosis* Beijing family with Han Chinese. *Proc Natl Acad Sci U S A* 112:8136–8141. <https://doi.org/10.1073/pnas.1424063112>.
13. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. 2013. *Mycobacterium tuberculosis* mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. *Nat Genet* 45:784–790. <https://doi.org/10.1038/ng.2656>.
14. Domenech P, Kolly GS, Leon-Solis L, Fallow A, Reed MB. 2010. Massive gene duplication event among clinical isolates of the *Mycobacterium tuberculosis* W/Beijing family. *J Bacteriol* 192:4562–4570. <https://doi.org/10.1128/JB.00536-10>.
15. Didelot X, Walker AS, Peto TE, Crook DW, Wilson DJ. 2016. Within-host evolution of bacterial pathogens. *Nat Rev Microbiol* 14:150–162. <https://doi.org/10.1038/nrmicro.2015.13>.
16. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR. 2003. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of *Mycobacterium tuberculosis*. *Mol Microbiol* 48:833–843. <https://doi.org/10.1046/j.1365-2958.2003.03474.x>.
17. Saini DK, Malhotra V, Tyagi JS. 2004. Cross talk between DevS sensor kinase homologue, Rv2027c, and DevR response regulator of *Mycobac-*

- terium tuberculosis*. FEBS Lett 565:75–80. <https://doi.org/10.1016/j.febslet.2004.02.092>.
18. Sherman DR, Voskuil MI, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. 2001. Regulation of the *Mycobacterium tuberculosis* hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A 98:7534–7539. <https://doi.org/10.1073/pnas.121172498>.
  19. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. 2003. Inhibition of respiration by nitric oxide induces a *Mycobacterium tuberculosis* dormancy program. J Exp Med 198:705–713. <https://doi.org/10.1084/jem.20030205>.
  20. Saini DK, Malhotra V, Dey D, Pant N, Das TK, Tyagi JS. 2004. DevR-DevS is a bona fide two-component system of *Mycobacterium tuberculosis* that is hypoxia-responsive in the absence of the DNA-binding domain of DevR. Microbiology 150:865–875. <https://doi.org/10.1099/mic.0.26218-0>.
  21. Boon C, Dick T. 2002. *Mycobacterium bovis* BCG response regulator essential for hypoxic dormancy. J Bacteriol 184:6760–6767. <https://doi.org/10.1128/JB.184.24.6760-6767.2002>.
  22. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of *Mycobacterium tuberculosis*. Annu Rev Microbiol 55:139–163. <https://doi.org/10.1146/annurev.micro.55.1.139>.
  23. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, Schoolnik GK. 2003. Transcriptional adaptation of *Mycobacterium tuberculosis* within macrophages: insights into the phagosomal environment. J Exp Med 198:693–704. <https://doi.org/10.1084/jem.20030846>.
  24. Shi L, Jung YJ, Tyagi S, Gennaro ML, North RJ. 2003. Expression of Th1-mediated immunity in mouse lungs induces a *Mycobacterium tuberculosis* transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci U S A 100:241–246. <https://doi.org/10.1073/pnas.0136863100>.
  25. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, Gomes A, Rustad T, Dolganov G, Glotova I, Abeel T, Mahwinney C, Kennedy AD, Allard R, Brabant W, Krueger A, Jaini S, Honda B, Yu WH, Hickey MJ, Zucker J, Garay C, Weiner B, Sisk P, Stolte C, Winkler JK, Van de Peer Y, Iazzetti P, Camacho D, Dreyfuss J, Liu Y, Dorhoi A, Mollenkopf HJ, Drogaris P, Lamontagne J, Zhou Y, Piquenet J, Park ST, Raman S, Kaufmann SH, Mohnep RP, Chelsky D, Moody DB, Sherman DR, Schoolnik GK. 2013. The *Mycobacterium tuberculosis* regulatory network and hypoxia. Nature 499:178–183. <https://doi.org/10.1038/nature12337>.
  26. Gonzalo Asensio J, Maia C, Ferrer NL, Barilone N, Laval F, Soto CY, Winter N, Daffe M, Gicquel W, Martin C, Jackson M. 2006. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in *Mycobacterium tuberculosis*. J Biol Chem 281:1313–1316. <https://doi.org/10.1074/jbc.C500388200>.
  27. Reed MB, Gagneux S, Deriemer K, Small PM, Barry CE, III. 2007. The W-Beijing lineage of *Mycobacterium tuberculosis* overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol 189:2583–2589. <https://doi.org/10.1128/JB.01670-06>.
  28. Homolka S, Niemann S, Russell DG, Rohde KH. 2010. Functional genetic diversity among *Mycobacterium tuberculosis* complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog 6:e1000988. <https://doi.org/10.1371/journal.ppat.1000988>.
  29. Rose G, Cortes T, Comas I, Coscolla M, Gagneux S, Young DB. 2013. Mapping of genotype-phenotype diversity among clinical isolates of *Mycobacterium tuberculosis* by sequence-based transcriptional profiling. Genome Biol Evol 5:1849–1862. <https://doi.org/10.1093/gbe/evt138>.
  30. Fallow A, Domenech P, Reed MB. 2010. Strains of the East Asian (W/Beijing) lineage of *Mycobacterium tuberculosis* are DosS/DosT-DosR two-component regulatory system natural mutants. J Bacteriol 192:2228–2238. <https://doi.org/10.1128/JB.01597-09>.
  31. Weiner B, Gomez J, Victor TC, Warren RM, Sloutsky A, Plikaytis BB, Posey JE, van Helden PD, Gey van Pittius NC, Koehrsen M, Sisk P, Stolte C, White J, Gagneux S, Birren B, Hung D, Murray M, Galagan J. 2012. Independent large scale duplications in multiple *M. tuberculosis* lineages overlapping the same genomic region. PLoS One 7:e26038. <https://doi.org/10.1371/journal.pone.0026038>.
  32. Domenech P, Rog A, Moolji JU, Radomski N, Fallow A, Leon-Solis L, Bowes J, Behr MA, Reed MB. 2014. Origins of a 350-kilobase genomic duplication in *Mycobacterium tuberculosis* and its impact on virulence. Infect Immun 82:2902–2912. <https://doi.org/10.1128/IAI.01791-14>.
  33. Manca C, Tsenova L, Barry CE, III, Bergtold A, Freeman S, Haslett PA, Musser JM, Freedman VH, Kaplan G. 1999. *Mycobacterium tuberculosis* CDC1551 induces a more vigorous host response *in vivo* and *in vitro*, but is not more virulent than other clinical isolates. J Immunol 162:6740–6746.
  34. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, Small PM, Pym AS. 2006. Impact of bacterial genetics on the transmission of isoniazid-resistant *Mycobacterium tuberculosis*. PLoS Pathog 2:e61. <https://doi.org/10.1371/journal.ppat.0020061>.
  35. Tsolaki AG, Gagneux S, Pym AS, Goguet de la Salmoniere YO, Kreiswirth BN, Van Soolingen D, Small PM. 2005. Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of *Mycobacterium tuberculosis*. J Clin Microbiol 43:3185–3191. <https://doi.org/10.1128/JCM.43.7.3185-3191.2005>.
  36. Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, Sherman DR. 2003. Deletion of RD1 from *Mycobacterium tuberculosis* mimics bacille Calmette-Guérin attenuation. J Infect Dis 187:117–123. <https://doi.org/10.1086/345862>.
  37. Hsu T, Hingley-Wilson SM, Chen B, Chen M, Dai AZ, Morin PM, Marks CB, Padiyar J, Goulding C, Gingery M, Eisenberg D, Russell RG, Derrick SC, Collins FM, Morris SL, King CH, Jacobs WR, Jr. 2003. The primary mechanism of attenuation of bacillus Calmette-Guérin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A 100:12420–12425. <https://doi.org/10.1073/pnas.1635213100>.
  38. Guinn KM, Hickey MJ, Mathur SK, Zakei KL, Grotzke JE, Lewinson DM, Smith S, Sherman DR. 2004. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of *Mycobacterium tuberculosis*. Mol Microbiol 51:359–370. <https://doi.org/10.1046/j.1365-2958.2003.03844.x>.
  39. Bitter W, Houben EN, Bottai D, Brodin P, Brown EJ, Cox JS, Derbyshire K, Fortune SM, Gao LY, Liu J, Gey van Pittius NC, Pym AS, Rubin EJ, Sherman DR, Cole ST, Brosch R. 2009. Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog 5:e1000507. <https://doi.org/10.1371/journal.ppat.1000507>.
  40. Sirakova TD, Dubey VS, Deb C, Daniel J, Korotkova TA, Abomolok B, Kolattukudy PE. 2006. Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in *Mycobacterium tuberculosis* under stress. Microbiology 152:2717–2725. <https://doi.org/10.1099/mic.0.28993-0>.
  41. Yuan Y, Crane DD, Barry CE, III. 1996. Stationary phase-associated protein expression in *Mycobacterium tuberculosis*: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 178:4484–4492.
  42. Peña D, Rovetta AI, Hernandez Del Pino RE, Amiano NO, Pasquinelli V, Pellegrini JM, Tateosian NL, Rolandelli A, Gutierrez M, Musella RM, Palmero DJ, Gherardi MM, Iovanna J, Chuluyan HE, Garcia VE. 2015. A *Mycobacterium tuberculosis* dormancy antigen differentiates latently infected bacillus Calmette-Guérin-vaccinated individuals. EBioMedicine 2:882–888.
  43. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, Arend SM, Ottenhoff TH, Klein MR. 2006. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of *Mycobacterium tuberculosis*. Microbes Infect 8:2052–2060. <https://doi.org/10.1016/j.micinf.2006.03.018>.
  44. Liu Y, Tan S, Huang L, Abramovitch RB, Rohde KH, Zimmerman MD, Chen C, Dartois V, VanderVen BC, Russell DG. 2016. Immune activation of the host cell induces drug tolerance in *Mycobacterium tuberculosis* both *in vitro* and *in vivo*. J Exp Med 213:809–825. <https://doi.org/10.1084/jem.20151248>.
  45. Bagchi G, Chauhan S, Sharma D, Tyagi JS. 2005. Transcription and autoregulation of the Rv3134c-*devR*-*devS* operon of *Mycobacterium tuberculosis*. Microbiology 151:4045–4053. <https://doi.org/10.1099/mic.0.28333-0>.
  46. Chauhan S, Tyagi JS. 2008. Cooperative binding of phosphorylated DevR to upstream sites is necessary and sufficient for activation of the Rv3134c-*devRS* operon in *Mycobacterium tuberculosis*: implication in the induction of DevR target genes. J Bacteriol 190:4301–4312. <https://doi.org/10.1128/JB.01308-07>.
  47. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, Nicol M, Niemann S, Kremer K, Gutierrez MC, Hilty M, Hopewell PC, Small PM. 2006. Variable host-pathogen compatibility in *Mycobacterium tuberculosis*. Proc Natl Acad Sci U S A 103:2869–2873. <https://doi.org/10.1073/pnas.0511240103>.
  48. Reed MB, Pichler VK, McIntosh F, Mattia A, Fallow A, Masala S, Domenech P, Zwerling A, Thibert L, Menzies D, Schwartzman K, Behr MA. 2009. Major *Mycobacterium tuberculosis* lineages associate with patient coun-

- try of origin. *J Clin Microbiol* 47:1119–1128. <https://doi.org/10.1128/JCM.02142-08>.
49. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE, III, Freedman VH, Kaplan G. 2001. Virulence of a *Mycobacterium tuberculosis* clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN- $\alpha$ /beta. *Proc Natl Acad Sci U S A* 98:5752–5757. <https://doi.org/10.1073/pnas.091096998>.
  50. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, Kaplan G, Barry CE, III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. *Nature* 431:84–87. <https://doi.org/10.1038/nature02837>.
  51. Sardiwal S, Kendall SL, Movahedzadeh F, Rison SC, Stoker NG, Djordjevic S. 2005. A GAF domain in the hypoxia/NO-inducible *Mycobacterium tuberculosis* DosS protein binds haem. *J Mol Biol* 353:929–936. <https://doi.org/10.1016/j.jmb.2005.09.011>.
  52. Falkow S. 1988. Molecular Koch's postulates applied to microbial pathogenicity. *Rev Infect Dis* 10(Suppl 2):S274–276.
  53. Cortes T, Schubert OT, Rose G, Arnvig KB, Comas I, Aebersold R, Young DB. 2013. Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in *Mycobacterium tuberculosis*. *Cell Rep* 5:1121–1131. <https://doi.org/10.1016/j.celrep.2013.10.031>.
  54. Newton-Foot M, Gey van Pittius NC. 2013. The complex architecture of mycobacterial promoters. *Tuberculosis (Edinb)* 93:60–74. <https://doi.org/10.1016/j.tube.2012.08.003>.
  55. Hu Y, Coates AR. 1999. Transcription of two sigma 70 homologue genes, *sigA* and *sigB*, in stationary-phase *Mycobacterium tuberculosis*. *J Bacteriol* 181:469–476.
  56. Burian J, Ramon-Garcia S, Sweet G, Gomez-Velasco A, Av-Gay Y, Thompson CJ. 2012. The mycobacterial transcriptional regulator *whiB7* gene links redox homeostasis and intrinsic antibiotic resistance. *J Biol Chem* 287:299–310. <https://doi.org/10.1074/jbc.M111.302588>.
  57. Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, Allen SS, Grosset JH, Jain SK, Lamichhane G, Manabe YC, McMurray DN, Nuermberger EL, Bishai WR. 2009. Role of the *dosR-dosS* two-component regulatory system in *Mycobacterium tuberculosis* virulence in three animal models. *Infect Immun* 77:1230–1237. <https://doi.org/10.1128/IAI.01117-08>.
  58. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J, Bishai WR. 2004. Dormancy phenotype displayed by extracellular *Mycobacterium tuberculosis* within artificial granulomas in mice. *J Exp Med* 200:647–657. <https://doi.org/10.1084/jem.20040646>.
  59. Gautam US, McGillivray A, Mehra S, Didier PJ, Midkiff CC, Kisse RS, Golden NA, Alvarez X, Niu T, Rengarajan J, Sherman DR, Kaushal D. 2015. DosS is required for the complete virulence of *Mycobacterium tuberculosis* in mice with classical granulomatous lesions. *Am J Respir Cell Mol Biol* 52:708–716. <https://doi.org/10.1165/rcmb.2014-0230OC>.
  60. Mehra S, Foreman TW, Didier PJ, Ahsan MH, Hudock TA, Kisse R, Golden NA, Gautam US, Johnson AM, Alvarez X, Russell-Lodrigue KE, Doyle LA, Roy CJ, Niu T, Blanchard JL, Khader SA, Lackner AA, Sherman DR, Kaushal D. 2015. The DosR regulon modulates adaptive immunity and is essential for *Mycobacterium tuberculosis* persistence. *Am J Respir Crit Care Med* 191:1185–1196. <https://doi.org/10.1164/rccm.201408-1502OC>.
  61. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE, III. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. *Infect Immun* 76:2333–2340. <https://doi.org/10.1128/IAI.01515-07>.
  62. Gautam US, Mehra S, Kaushal D. 2015. *In-vivo* gene signatures of *Mycobacterium tuberculosis* in C3HeB/FeJ mice. *PLoS One* 10:e0135208. <https://doi.org/10.1371/journal.pone.0135208>.
  63. Comas I, Chakravarti J, Small PM, Galagan J, Niemann S, Kremer K, Ernst JD, Gagneux S. 2010. Human T cell epitopes of *Mycobacterium tuberculosis* are evolutionarily hyperconserved. *Nat Genet* 42:498–503. <https://doi.org/10.1038/ng.590>.
  64. Daniel J, Deb C, Dubey VS, Sirakova TD, Abomoelak B, Morbidoni HR, Kolattukudy PE. 2004. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in *Mycobacterium tuberculosis* as it goes into a dormancy-like state in culture. *J Bacteriol* 186:5017–5030. <https://doi.org/10.1128/JB.186.15.5017-5030.2004>.
  65. Minch K, Rustad T, Sherman DR. 2012. *Mycobacterium tuberculosis* growth following aerobic expression of the DosR regulon. *PLoS One* 7:e35935. <https://doi.org/10.1371/journal.pone.0035935>.
  66. Cohen T, Colijn C, Murray M. 2008. Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. *Proc Natl Acad Sci U S A* 105:16302–16307. <https://doi.org/10.1073/pnas.0808746105>.
  67. Gagneux S, Small PM. 2007. Global phylogeography of *Mycobacterium tuberculosis* and implications for tuberculosis product development. *Lancet Infect Dis* 7:328–337. [https://doi.org/10.1016/S1473-3099\(07\)70108-1](https://doi.org/10.1016/S1473-3099(07)70108-1).
  68. Saini V, Cumming BM, Guidry L, Lamprecht DA, Adamson JH, Reddy VP, Chinta KC, Mazorodze JH, Glasgow JN, Richard-Greenblatt M, Gomez-Velasco A, Bach H, Av-Gay Y, Eoh H, Rhee K, Steyn AJ. 2016. Ergothioneine maintains redox and bioenergetic homeostasis essential for drug susceptibility and virulence of *Mycobacterium tuberculosis*. *Cell Rep* 14:572–585. <https://doi.org/10.1016/j.celrep.2015.12.056>.
  69. Honaker RW, Leistikow RL, Bartek IL, Voskuil MI. 2009. Unique roles of DosT and DosS in DosR regulon induction and *Mycobacterium tuberculosis* dormancy. *Infect Immun* 77:3258–3263. <https://doi.org/10.1128/IAI.01449-08>.
  70. Kim MJ, Park KJ, Ko IJ, Kim YM, Oh JI. 2010. Different roles of DosS and DosT in the hypoxic adaptation of mycobacteria. *J Bacteriol* 192:4868–4875. <https://doi.org/10.1128/JB.00550-10>.
  71. Sousa EHS, Tuckerman JR, Gonzalez G, Gilles-Gonzalez MA. 2007. DosT and DevS are oxygen-switched kinases in *Mycobacterium tuberculosis*. *Protein Sci* 16:1708–1719. <https://doi.org/10.1110/ps.072897707>.
  72. Sivaramakrishnan S, Ortiz de Montellano PR. 2013. The DosS-DosT/DosR mycobacterial sensor system. *Biosensors* 3:259–282. <https://doi.org/10.3390/bios3030259>.
  73. Broset E, Martin C, Gonzalo-Asensio J. 2015. Evolutionary landscape of the *Mycobacterium tuberculosis* complex from the viewpoint of PhoPR: implications for virulence regulation and application to vaccine development. *mBio* 6(5):e01289-15. <https://doi.org/10.1128/mBio.01289-15>.
  74. Veyrier F, Said-Salim B, Behr MA. 2008. Evolution of the mycobacterial SigK regulon. *J Bacteriol* 190:1891–1899. <https://doi.org/10.1128/JB.01452-07>.
  75. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. 1997. Restricted structural gene polymorphism in the *Mycobacterium tuberculosis* complex indicates evolutionarily recent global dissemination. *Proc Natl Acad Sci U S A* 94:9869–9874. <https://doi.org/10.1073/pnas.94.18.9869>.
  76. Sambrook J, Fritsch EF, Maniatis T. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  77. Pelicic V, Jackson M, Reyat JM, Jacobs WR, Jr, Gicquel B, Guilhot C. 1997. Efficient allelic exchange and transposon mutagenesis in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 94:10955–10960. <https://doi.org/10.1073/pnas.94.20.10955>.
  78. Lew JM, Kapopoulou A, Jones LM, Cole ST. 2011. TubercuList—10 years after. *Tuberculosis (Edinb)* 91:1–7. <https://doi.org/10.1016/j.tube.2010.09.008>.
  79. Domenech P, Reed MB. 2009. Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from *Mycobacterium tuberculosis* grown in vitro: implications for virulence studies. *Microbiology* 155:3532–3543. <https://doi.org/10.1099/mic.0.029199-0>.
  80. Yu J, Othman MI, Farjo R, Zarepari S, MacNee SP, Yoshida S, Swaroop A. 2002. Evaluation and optimization of procedures for target labeling and hybridization of cDNA microarrays. *Mol Vis* 8:130–137.
  81. Applied Biosystems. 2005. Real-time PCR systems: Applied Biosystems 7900HT fast real-time PCR system and 7300/7500 real-time PCR systems. Chemistry guide. Part no. 4348358, re E. Applied Biosystems, Foster City, CA. [http://www3.appliedbiosystems.com/cms/groups/mcb\\_marketing/documents/generaldocuments/cms\\_041440.pdf](http://www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_041440.pdf).
  82. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:457–481. <https://doi.org/10.1080/01621459.1958.10501452>.
  83. Parish T, Wheeler PR. 1998. Preparation of cell-free extracts from mycobacteria. *Methods Mol Biol* 101:77–89.
  84. Slayden RA, Barry CE, III. 2001. Analysis of the lipids of *Mycobacterium tuberculosis*. *Methods Mol Med* 54:229–245. <https://doi.org/10.1385/1-59259-147-7:229>.